We previously developed a radioreceptor assay which is presumably specific for detection of blocking-type anti-TSH receptor (TSHR) antibodies using unsolubilized porcine TSHR.
THYROID stimulation blocking antibody (TSBAb) has been considered to be specific for primary atrophic hypothyroidism.
However, several authors recently reported that TSBAb is sometimes found in sera from Graves' patients [1] [2] [3] [4] [5] [6] [7] . But, its prevalence varies widely from 0 to 71.8%, and there is no established conclusion as to this problem.
One major reason for the above discrepancy may be that the conventional method for TSBAb measurement is an unstable bioassay, wherein TSBAb is expressed as blocking activity of the sera to the cAMP increase when thyroid cells or TSH receptor (TSHR)-transfected cells are stimulated with TSH. Although the conventional bioassay for TSBAb is good for primary atrophic hypothyroidism, it may fail when analyzing Graves' sera because the thyroid stimulating antibody (TSAb) present in sera interferes with the cAMP increase, resulting in false negatives for TSBAb especially in sera with strongly positive TSAb. To avoid TSAb interference with TSBAb measurement in Graves' sera, Kim et al. em- ployed TSHR-LH/CGR chimeric receptor-expressing MC2 cells, and found TSBAb in 18.5% of sera from Graves' patients [7] . With MC2 cells, TSBAb measurement according to the conventional procedure is expected not to be interfered with by TSAb because MC2 cells, in which the TSAb-sensitive portion of THSR (amino acid residues 90-163) is replaced with residues 91-166 of the LH/CG recep- TADA et al. tor, are insensitive to TSAb [7, 8] .
We previously reported that blocking type anti-TSHR antibodies could be separately measured with a radioreceptor assay using unsolubilized TSHR [9] . Our method can also decrease, at least partially, the interference by TSAb and simpler in procedure than bioassays. Therefore, we measured blocking type anti-TSHR antibodies in the sera from 30 patients with untreated Graves' disease using our radioreceptor assay method, and compared our results with the results obtained by bioassay, and examined the relation of blocking type anti-TSHR anti-bodies to clinical characteristics.
To avoid confusion, we shall refer to blocking antibody measured with our radioreceptor assay as "blocking" TSH binding inhibitory immunoglobulin (TBII), and blocking antibody measured by the conventional bioassay simply as TSBAb in the rest of this report.
Materials and Methods

Serum samples
Sera from 30 untreated patients with Graves' disease were studied.
The diagnosis of Graves' disease was confirmed by continuous increase of serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations, decreased serum TSH, and positive anti-TSHR antibody and/or high radioiodine thyroid uptake.
Patients were treated with anti-thyroid agent, methimazole, with an initial dose of 30 mg per day, and the dose was gradually decreased after normalization of thyroid hormones. To obtain the immunoglobulin (Ig) fraction, 50 pl of serum was precipitated with 500 pl of 0.15 M NaCI solution containing 15% polyethylene glycol 6000 (PEG) at 2,000 x g for 20 min. The pellets were suspended in 100 pl of assay buffer A [10 mM Tris-HC1 buffer, pH 7.4, with 0.1% bovine serum albumin] containing 0.05 M NaCI. b) Preparation of porcine thyroid particulate membrane suspension Twenty grams of porcine thyroid gland was minced and washed with physiological saline, to which 70 mL of preparation solution [l0 mM Tris-HC1 buffer, pH 7.4, with 0.93 g/L of iodoacetamide (Wako Pure Chemical Co., Osaka, Japan), 0.01 g/L leupeptin (Funakoshi Co., Tokyo, Japan), 0.01 g/L soybean trypsin inhibitor (Sigma-Aldrich, Missouri, USA), 200 kIU/mL aprotinin (Union Chemical Co., Tokyo, Japan), and 0.15 M NaCI] was then added. The mixture was homogenized 4 times with a Polytron homogenizer for 15 sec, and then 4 times with a Potter homogenizer at 1,500 rpm for 15 sec. The homogenate was centrifuged at 500 x g (4°C; 30 min) and the supernatant was centrifuged at 100,000 x g (4°C; 30 min). The pellet was resuspended in 20 mL of preparation solution containing 0.15 M NaCI, homogenized 3 times with a Polytron homogenizer for 10 sec, and centrifuged at 1,500 x g (4°C; 30 min). The supernatant was used as the porcine thyroid particulate membrane suspension, and stored at -80°C. c) Preparation of solubilized porcine thyroid membrane Dodecylpolyethyleneglycoether (Thesit®: Roche diagnostics, Basel, Switzerland) was added to the porcine thyroid membrane suspension (final concentration, 1%), and the mixture was gently stirred for 1 hr at 4°C. It was then centrifuged at 100,000 x g for 30 min, and the supernatant was used as the solubilized porcine TSHR solution. The solution was stored at -80°C until use for TBII assays . Measurement of TSAb and TSBAb with FRTL-S cells a) Serum immunoglobulin preparation Two hundred microliters of serum was precipitated with 800 pl of 0.15 M NaCI solution containing 18% polyethylene glycol 6000 (PEG) at 2,000 x g for 20 min. The pellets were suspended in 200 pl of assay buffer B (pH 7.4) containing 8.0 mM Na2HP04, 1.5 mM KH2P04, 2.7 mM KCI, 0.9 mM CaCl2, 0.5 mM MgCl2 6H20, 0.5 mM 3-isobutyl-l-methylxanthine, 0.1 % glucose, 1.0% bovine serum albumin, 100 pg /ml streptomycin and 100 U/ml penicillin. b) Preparation of FRTL-5 cells Rat thyroid cell line FRTL-5 was maintained in 6 H [Ham's F12K medium containing 5% fetal bovine serum, TSH (10 mU/mL), transferrin (5 pg/mL), insulin (10 mg/mL), somatostatin (10 mg/mL), cortisone (10 nM), and glycyl-L-histidyl-L-lysine acetate (10 ng/mL)] medium. FRTL-5 cells were harvested, and 2 x 104 cells per well were seeded into 96-well culture plates. After 6 days of incubation in 6 H medium, cells were incubated in 5 H medium [which is 6 H medium lacking TSH] for 4 days and used for TSAb or TSBAb assays. c) Measurement of thyroid stimulating antibody (TSAb) After the above cells were washed with assay buffer B, 100 pl of sample Ig fraction in assay buffer B was added, and the cells were incubated for 3 hr at 37°C. The CAMP concentration in the supernatant was measured with a commercially available radioimmunoassay kit ("CyclicAMP Kit YAMASA", Yamasa Shoyu Co. Ltd., Chiba, Japan). TSAb activity was expressed as the percent increase in the cAMP level by comparison to normal pooled immunoglobulin [11] . The normal cut-off value of TSAb was <140%. d) Measurement of thyroid stimulation blocking antibody (TSBAb) After the cells were washed with assay buffer B, 100 p1 of sample Ig fraction and bovine TSH were added to the final concentration of 100 pU/mL. The cells were incubated for 3 hr at 37°C in assay buffer B. The cAMP concentration in the supernatant was measured with a commercially available radioimmunoassay kit (Yamasa Shoyu Co. Ltd., Chiba, Japan). TSBAb activity, expressed as the percent inhibition of cAMP release, was calculated as follows [ 
Results
Prevalence of blocking antibody and relation between radioreceptor assay and conventional bioassay
The results of the measurement of anti-TSHR antibodies and the clinical profiles of the patients are summarized in Table 1 . Blocking TBII was positive in 9 of 30 sera (30%) from the patients with Graves' disease, and the blocking TBII activity was correlated with the total TBII value (Fig. la) . On the other hand, TSBAb determined with the conventional bioassay was positive in only 2 sera (6.7%), and no correlation was observed with the TSAb activity (Fig. ib) . Although there was a slight correlation between blocking TBII and bioassay TSBAb, it was not significant (Fig. lc) . There was also no correlation between other radioreceptor assays and bioassays (r=0.264 for blocking TBII vs TSAb, 0.192 for total TBII vs TSBAb and 0.265 for total TBII vs TSAb, respectively). In cases 3, 6,10,14,15 and 19, in which TSAb activities were rather high, TSBAb was not detected whereas blocking TBII was positive.
Relation of blocking antibody to clinical characteristics
There was no correlation of blocking TBII activity with goiter, thyroid hormone level, or proptosis (data not shown). However, the time required for FT4 normalization after initiation of anti-thyroid drug therapy (Fig. 2) showed a tendency to be shorter in blocking TBII positive patients than that in negative ones. There was no relation of total TBII, TSBAb, or TSAb with these clinical parameters, including the time required for FT4 normalization. Several authors have reported that TSBAb is sometimes found in sera from patients with Graves' disease. The results of previous reports on the prevalence of TSBAb in Graves' disease are summarized in Table 2 , which shows that this prevalence varies widely from 0 to 71.8%, and there is no established conclusion about this problem. In some reports, the sample sera was drawn from patients under or after treatment, which may result in a lower prevalence of anti-TSHR antibody. However, one major reason for the above discrepancy may be the use of the conventional TSBAb bioassay. TSBAb bioassay sometimes produces varied results depending on the condition of the cells, and in principle it is impossible to obtain accurate readings of TSBAb activities when TSAb is also present.
In the approach of Kim et al., with TSHR-LH /CGR chimeric receptor-expressing MC2 cells [7] , interference by TSAb is expected to be minimal, because MC2 cells have TSHR-LH/CGR chimeric receptor, in which the TSAb-sensitive portion of THSR (amino acid residues 90-163) is replaced with residues 91-166 of the LH/CG receptor. The advantage of their approach is that it has a distinct molecular basis. TSAbs that interact with the epitope in residues 90-163 of THSR obviously have no effect on the assay with MC2 cells. However, there are TSAbs which interact with another portion of TSHR, and furthermore their activities are often higher [8] , although the major population of TSAbs interact with the epitope in residues 90-163. The chimeric receptor approach thus always fails to completely prevent the interference by such TSAbs.
We previously reported that TSBAb could be measured separately by using a radioreceptor assay with a modified TSHR membrane preparation [9] , although it is difficult to prove how completely the separate measurement may be performed. In contrast to the chimeric receptor method, our approach does not have a distinct molecular basis. It may be supposed that most TSAbs natively do not block TSH binding when they interact with TSHR, but that TSBAbs do when TSHR is kept in a near-native conformation by the use of gentle preparation procedures without solubilization, whereas solubilized TSHR used in the conventional TBII may be degenerated to the point that both TSAb and TSBAb block the binding of TSH. In the present study, cases 3, 6,10,14,15 and 19 showed rather high TSAb activities, among the samples in which blocking TBII was detected, despite the failure of the TSBAb bioassay to detect activity. Moreover, an obvious advantage of our radioreceptor assay method is that the procedure is far less complicated than bioassays.
We found blocking TBII in 9 of 30 sera (30%) On the other hand, Kosugi et al. detected TSAb in a patient with idiopathic myxedema with TSBAb using mutant TSHR expressing cos-7 cells [12] . Therefore, it is suggested that multiple anti-TSHR antibodies with various activities are produced in these diseases which may be considered as autoimmune TSH receptor diseases [13] .
There was no correlation of blocking TBII activity with the clinical characteristics examined. Although Kim et al. found that their TSBAb had a significant association with Graves' ophthalmopathy [7] , our study did not find any correlation of the blocking TBII with the extent of proptosis of the patients.
We expected that higher blocking TBII activity might make Graves' disease more controllable and found that the duration required to make the patients euthyroid after the initiation of anti-thyroid agents was slightly shorter in the patients with high blocking TBII. Although it is widely accepted that the pathophysiology of Graves' disease is strongly dominated by TSAbs, for which various procedures of sensitive assay have been proposed [14] , our results suggest that TSBAbs have some modulating effect. It is possible that the effect of blocking TBII may become more pronounced in the long term prognosis, and that blocking TBII may be associated with a higher remission rate, although we were not able to examine this aspect in the present study.
